CEPHEID for CEPHEID

Medical/Disease Research/Clinical Labs MED

See page five Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues HR 436/ S 17, Protect Medical Innovation Act of 2011 HR 488, Save Our Medical Devices Act of 2011 HR 755, Investing in Our Future Act of 2011 HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011 HR 2182 Generating Antibiotic Incentives Now (GAIN) S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011

Contacted: Food & Drug Administration (FDA); Natl Institutes of Health (NIH); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 2182 (112th), H.R. 965 (112th), H.R. 488 (112th), H.R. 755 (112th), H.R. 436 (112th)

Health Issues HCR

See page three Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues HR 436/ S 17, Protect Medical Innovation Act of 2011 HR 488, Save Our Medical Devices Act of 2011 HR 755, Investing in Our Future Act of 2011 HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011 HR 2182 Generating Antibiotic Incentives Now (GAIN) S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ)

Bills named: H.R. 755 (112th), H.R. 436 (112th), H.R. 488 (112th), H.R. 2182 (112th), H.R. 965 (112th)

Medicare/Medicaid MMM

See page 7 Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues HR 436/ S 17, Protect Medical Innovation Act of 2011 HR 488, Save Our Medical Devices Act of 2011 HR 755, Investing in Our Future Act of 2011 HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011 HR 2182 Generating Antibiotic Incentives Now (GAIN) S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); SENATE; Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 965 (112th), H.R. 436 (112th), H.R. 488 (112th), H.R. 2182 (112th), H.R. 755 (112th)